Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension

References

• WHO, facts and figuresWorld Health Organization2008
   Web of Science ®Google Scholar
• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet2005365945521722315652604
   PubMed Web of Science ®Google Scholar
• CifkovaRErdineSFagardRPractice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelinesJ Hypertens200321101779178614508180
   PubMedGoogle Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSKramerHHypertension treatment and control in five European countries, Canada, and the United StatesHypertension2004431101714638619
   PubMed Web of Science ®Google Scholar
• WangYRAlexanderGCStaffordRSOutpatient hypertension treatment, treatment intensification, and control in Western Europe and the United StatesArch Intern Med2007167214114717242314
   PubMedGoogle Scholar
• ManciaGGrassiGSystolic and diastolic blood pressure control in antihypertensive drug trialsJ Hypertens20022081461146412172300
   PubMed Web of Science ®Google Scholar
• FranklinSSJacobsMJWongNDL’ItalienGJLapuertaPPredominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) IIIHypertension200137386987411244010
   PubMed Web of Science ®Google Scholar
• WilliamsBLindholmLHSeverPSystolic pressure is all that mattersLancet200837196312219222118561995
   PubMed Web of Science ®Google Scholar
• BramlagePClinical practice and recent recommendations in hypertension management – reporting a gap in a global survey of 1259 primary care physicians in 17 countriesCurrent Medical Research and Opinions2007234783791
   PubMed Web of Science ®Google Scholar
• McCombsJSNicholMBNewmanCMSclarDAThe costs of interrupting antihypertensive drug therapy in a Medicaid populationMed Care19943232142268145599
   PubMed Web of Science ®Google Scholar
• JonesJKGorkinLLianJFStaffaJAFletcherAPDiscontinuation of and changes in treatment after start of new courses of anti-hypertensive drugs: a study of a United Kingdom populationBMJ199531170002932957633238
   PubMedGoogle Scholar
• WaeberBBurnierMBrunnerHRCompliance with antihypertensive therapyClin Exp Hypertens1999215–697398510423118
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakAGuidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072561105118717563527
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetesDiabetes Care200427Suppl 1S15S3514693923
   PubMedGoogle Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study GroupLancet19983519118175517629635947
   PubMed Web of Science ®Google Scholar
• JamersonKABakrisGLWunCCRationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH trial): the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertensionAm J Hypertens200417979380115363822
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney diseaseAm J Kidney Dis2004435 Suppl 1S1S29015114537
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJMorrisJKJordanREValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ20033267404142712829555
   PubMed Web of Science ®Google Scholar
• KocharMGuthrieRTriscariJKassler-TaubKReevesRAMatrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertensionAm J Hypertens199912(8 Pt 1):79780510480473
   PubMed Web of Science ®Google Scholar
• GerbinoPPShoheiberOAdherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agentsAm J Health Syst Pharm200764121279128317563050
   PubMed Web of Science ®Google Scholar
• DicksonMPlauschinatCACompliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapyAm J Cardiovasc Drugs200881455018303937
   PubMed Web of Science ®Google Scholar
• BangaloreSFixed-dose combination improves medication complianceJ Clin Hypertens (Greenwich)2006Suppl AA72
   Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• BakrisGLTotoRDMcCulloughPAPurkayasthaDDavisPEffects of different ACE inhibitor combinations on albuminuria: results of the GUARD studyKidney Int20081303130918354383
   PubMed Web of Science ®Google Scholar
• BakrisGMolitchMHewkinADifferences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndromeDiabetes Care200629122592259717130190
   PubMed Web of Science ®Google Scholar
• AllemannYFraileBLambertMBarbierMFerberPIzzoJLEfficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) studyJ Clin Hypertens (Greenwich)200810318519418326958
   PubMed Web of Science ®Google Scholar
• ChrysantSGMelinoMKarkiSLeeJHeyrmanRThe combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety studyClin Ther200830458760418498909
   PubMed Web of Science ®Google Scholar
• Avalide prescribing information. 2007. Available from: www.avaproavalide.com/pi_pop.aspx
   Google Scholar
• CoAprovel summary of product characteristics. 2007. Available from: emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=15112
   Google Scholar
• RaskinPGuthrieRFlackJReevesRSainiRThe long-term anti-hypertensive activity and tolerability of irbesartan with hydrochlorothiazideJ Hum Hypertens1999131068368710516738
   PubMed Web of Science ®Google Scholar
• LittlejohnTIIISainiRKassler-TaubKChrysantSGMarburyTLong-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studiesClin Exp Hypertens19992181273129510574413
   PubMed Web of Science ®Google Scholar
• MarinoMRLangenbacherKFordNFUdermanHDPharmacokinetics and pharmacodynamics of irbesartan in healthy subjectsJ Clin Pharmacol19983832462559549663
   PubMed Web of Science ®Google Scholar
• SchindlerCFerrarioCMOlmesartan for the treatment of arterial hypertensionFuture Cardiol200844357372
   PubMedGoogle Scholar
• MarinoMLagenbacherKEffect of hydrochlorothiazide on the pharmacokinetics and pharmadodynamics of angiotensin II blocker irbesartanDrug Invest1997383391
   Google Scholar
• CocaACalvoCSobrinoJOnce-daily fixed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertensionClin Ther200325112849286414693309
   PubMed Web of Science ®Google Scholar
• BobrieGDeloncaJMoulinCGiacominoAPostel-VinayNAsmarRA home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinationsAm J Hypertens200518111482148816280286
   PubMed Web of Science ®Google Scholar
• NeutelJMSmithDAmbulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertensionJ Int Med Res200533662063116372579
   PubMed Web of Science ®Google Scholar
• NeutelJMSaundersEBakrisGLThe efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trialJ Clin Hypertens (Greenwich)200571057858616227760
   PubMedGoogle Scholar
• SowersJRNeutelJMSaundersEAntihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetesJ Clin Hypertens (Greenwich)20068747048016849900
   PubMedGoogle Scholar
• OfiliEOFerdinandKCSaundersEIrbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapyJ Natl Med Assoc200698461862616623075
   PubMed Web of Science ®Google Scholar
• CushmanWCNeutelJMSaundersEEfficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapyAm J Geriatr Cardiol2008171273618174757
   PubMedGoogle Scholar
• SaundersECableGNeutelJPredictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) studyJ Clin Hypertens (Greenwich)2008101273318174768
   PubMed Web of Science ®Google Scholar
• NeutelJMFranklinSSOparilSBhaumikAPtaszynskaALapuertaPEfficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertensionJ Clin Hypertens (Greenwich)200681285085717170610
   PubMedGoogle Scholar
• FranklinSSNeutelJMDonovanMBouzamondoHIrbesartan/hydrochlorothiazide as initial therapy: subanalysis in patients with systolic BP > 180 mmHg and diastolic BP > 110 mmHg, efficacy and safetyJ Hypertens2008Suppl 1S159
   Google Scholar
• NeutelJMFranklinSSLapuertaPBhaumikAPtaszynskaAA comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertensionJ Hum Hypertens20082226627417928878
   PubMed Web of Science ®Google Scholar
• FranklinSLapuertaPCoxDDonovanMInitial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapyJ Clin Hypertens (Greenwich)2007912 Suppl 5152218046108
   PubMedGoogle Scholar
• WeirMRNeutelJMBhaumikAde ObaldiaMELapuertaPThe efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular riskJ Clin Hypertens (Greenwich)2007912 Suppl 5233018046109
   PubMedGoogle Scholar
• SunNLJingSChenJ[The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension]Zhonghua Xin Xue Guan Bing Za Zhi200533761862116080809
   PubMedGoogle Scholar
• SchmiederREKreklerM[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ]MMW Fortschr Med2005147Suppl 39710116261944
   PubMedGoogle Scholar
• StrutzFBramlagePPaarWDEffect of three months’ treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patientsCurr Med Res Opin20052191433144016197662
   PubMed Web of Science ®Google Scholar
• SharmaAMBramlagePKirchWAntihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension: a prospective, open-label studyClin Drug Investig20052512765776
   PubMed Web of Science ®Google Scholar
• SchraderJBramlagePLudersSThoenesMSchirmerAPaarDWBP goal achievement in patients with uncontrolled hypertension: results of the treat-to-target post-marketing survey with irbesartanClin Drug Investig20072711783796
   PubMed Web of Science ®Google Scholar
• KintscherUBramlagePPaarWDThoenesMUngerTIrbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patientsCardiovasc Diabetol200761217407587
   PubMed Web of Science ®Google Scholar
• TurnbullFEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• WeberMAJuliusSKjeldsenSEBlood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialLancet200436394262049205115207957
   PubMed Web of Science ®Google Scholar
• FranklinSLapuertaPCoxDDonovanMInitial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapyJ Clin Hypertens (Greenwich)2007912 Suppl152218046108
   PubMedGoogle Scholar
• WeirMRNeutelJMBhaumikAObaldiaMELapuertaPThe efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular riskJ Clin Hypertens (Greenwich)2007912 Suppl233018046109
   PubMedGoogle Scholar